



Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/728,082		
				Filing Date	December 3, 2003		
				First Named Inventor	Cruz		
				Group Art Unit	1654		
				Examiner Name	Marcela M.C. Garcia		
				Attorney Docket Number	24492-013 CIP		
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A16	4,464,363	08/07/84	Higuchi et al.	424	232	
	*A17	4,997,950	03/05/91	Murphy et al.	548	303	
	*A18	5,993,850	11/30/99	Sankaram et al.	424	450	
	*A19	6,150,327	11/21/00	Sinn et al.	514	8	
	*A20	6,423,685 B1	07/23/02	Drummond et al.	514	12	
	*A21	6,593,295 B2	07/15/03	Bridon et al.	514	2	
	*A22	6,686,179 B2	02/03/04	Fleer et al.	435	69.7	

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A23	2002/0119146 A1	08/29/02	Dupre, John	424	139.1	
	*A24	2002/0182728 A1	12/05/02	Ramiya et al.	435	366	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B16	CN	1169827C	SAN SHENG	10/06/04		
	B17	EP	0 380 230 B1	APHTON CORPORATION	08/01/90		
	B18	WO	95/31214	LONDON HEALTH ASSOCIATION	11/23/95		
	B19	WO	02/10195 A2	THERATECHNOLOGIES INC.	02/07/02		
	B20	WO	2007/041833 A1	WARATAH PHARMACEUTICALS	04/19/07		
	B21	WO	2007/062531 A1	WARATAH PHARMACEUTICALS	06/07/07		
	B22	WO	2007/095737 A1	WARATAH PHARMACEUTICALS	08/30/07		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C48	Ahmed et al., "High and Low Affinity Receptors Mediate Growth Effects of Gastrin and Gastrin Gly on DLD-1 Human Colonic Carcinoma Cells", <i>FEBS Letters</i> , 556:199-203 (2004)

C49	Baggio et al., "Therapeutic approaches to preserve islet mass in type 2 diabetes", <i>Annual Review of Medicine</i> , 57:265-281 (2006)
C50	Baldwin, G.S., "The role of gastrin and cholecystokinin in normal and neoplastic gastrointestinal growth", <i>J. Gastroenterol. Hepatol.</i> , 10(2):215-232 (1995)
C51	Baldwin et al., "Measurement of Gastrin and Transforming Growth Factor α Messenger RNA Levels in Colonic Carcinoma Cell Lines by Quantitative Polymerase Chain Reaction", <i>Cancer Research</i> , 52:2261-2267 (1992)
C52	Behr et al., "Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors", <i>J. Nuclear Medicine</i> , 40(6):1029-1044 (1999)
C53	Bentley et al., "Human Gastrin: Isolation, Structure and Synthesis", <i>Nature</i> , 209:583-585 (1966)
C54	Bonato et al., "Guinea Pig 33-Amino Acid Gastrin", <i>Life Science</i> , 39:959-964 (1986)
C55	Brand et al., "Differential Gastrin Gene Expression in Rat Gastrointestinal Tract and Pancreas during Neonatal Development", <i>J. Biol. Chem.</i> , 263(11):5341-5347, (1988)
C56	Brand et al., "Gastrin Gene Expression and Regulation in Rat Islet Cell Lines", <i>J. Biol. Chem.</i> , 263:16597-16603 (1994)
C57	Brand et al., "Prolonged Efficacy of Islet Neogenesis Therapy with Gastrin and TGF α in Mature Rats with Preexisting Diabetes", <i>Diabetes</i> , 50(Suppl 2):A338 (Abstract) (2001)
C58	Brenna et al., "Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: establishment of a dose response relationship", <i>Gut</i> , 33(10):1303-1306 (1992)
C59	Carlsson et al., "Gastrin and gastric enterochromaffin-like cell carcinoids in the rat", <i>Digestion</i> , 47(Suppl 1): 17-23, "Discussion", pp 49-52 (1990)
C60	Chen et al., "Time course of hypertrophic and ultrastructural responses of rat stomach enterochromaffin-like cells to sustained hypergastrinemia", <i>Cell Tissue Res</i> , 284(1):55-63 (1994)
C61	Dembinski et al., "Stimulation of Pancreatic Growth by Secretin, Caerulein, and Pentagastrin", <i>Endocrinology</i> , 106(1):323-328 (1980)
C62	Drucker, D.J., "Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis", <i>Molecular Endocrinology</i> , 17(2):161-171 (2003)
C63	Dupre et al., "Effects of Secretin, Pancreozymin, or Gastrin on the Response of the Endocrine Pancreas to Administration of Glucose or Arginine in Man", <i>Journal of Clinical Investigation</i> , 48:745-757 (1969)
C64	Durrant et al., "Co-stimulation of Gastrointestinal Tumour Cell Growth by Gastrin, Transforming Growth Factor α and Insulin Like Growth Factor-1", <i>Brit. J. Cancer</i> , 63:67-70 (1991)
C65	Elder et al., "Effect of urogastrone on gastric secretion and plasma gastrin levels in normal subjects", <i>Gut</i> , 16 (11):887-893 (1975)
C66	Elder et al., "Effect of urogastrone in the Zollinger-Ellison syndrome", <i>The Lancet</i> , 2(7932):424-427 (1975)
C67	Ennis et al., "The EGF receptor system as a target for antitumor therapy", <i>Cancer Invest.</i> , 9(5):553-562 (1991)
C68	GenBank Accession No. AAH69762
C69	GenBank Accession No. NP_000796
C70	Gil et al., "Polymeric Biomaterials as Drug Delivery Systems", <i>Boletim et Biotecnologia</i> , 72:13-19 (2002)
C71	Han et al., "Altered pharmacokinetics and liver targetability of methotrexate by conjugation with lactosylated albumins", <i>Drug. Deliv.</i> , 8(3):125-134 (2001)
C72	Jensen, R.T., "Gastrinoma as a model for prolonged hypergastrinemia in the human" in <i>Gastrin</i> , Chapter 29, pp 373-393, Raven Press Ltd., New York (1993)
C73	Kopin et al., "The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands", <i>J Biol Chem</i> , 270(10):5019-5023 (1995)
C74	Korc et al., "Regulation of Protein Synthesis in Normal and Diabetic Rat Pancreas by Cholecystokinin", <i>Am J Physiol</i> , 241:G116-G121 (1981)
C75	Korc, M.J., "Islet Growth Factors: Curing Diabetes and Preventing Chronic Pancreatitis?", <i>Clin. Invest.</i> , 92:1113-1114 (1993)

C76	Kuntz et al., "Cholecystokinin Octapeptide: A Potential Growth Factor for Pancreatic Beta Cells in Diabetic Rats", <i>Journal of Pancreas</i> , 5(6):464-475 (2004)
C77	Larsson et al., "Pancreatic gastrin in foetal and neonatal rats", <i>Nature</i> , 262:609-610 (1976)
C78	Lima-Leite et al., "Synthesis and Biological Activities of the Human Gastrin analogs", <i>Brazilian Journal of Medical and Biological Research</i> , 29:1253-1263 (1996)
C79	Low et al., "Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists", <i>J. Med. Chem.</i> , 43:3505-3517 (2000)
C80	Pederson et al., "Effect of Cholecystokinin, Secretin, and Gastric Inhibitory Polypeptide on Insulin Release From the Isolated Perfused Rat Pancreas", <i>Can J Physiol Pharmacol</i> , 57:1233-1237 (1979)
C81	Sacchi et al., "Nesidioblastosis and Islet Cell Changes Related to Endogenous Hypergastrinemia", <i>Virchows Archiv[Cell Path]</i> , 48:261-276 (1985)
C82	Sandvik et al., "Biological Activity of Carboxy Terminal Gastrin analogs", <i>European Journal of Pharmacology</i> , 364:199-203 (1999)
C83	"SIGMA: Designing Custom Peptides", http://www.sigma-genosys.com/peptide_design.asp , pp 1-2
C84	Shu-qi et al., "Chemical Modification of Protein and Biochemical Drugs", <i>Chinese Journal of Biochemical Pharmaceutics</i> , 19(5):1-7 (1998)
C85	Taylor et al., "Serum gastrin in patients with chronic renal failure", <i>Gut</i> , 21(12):1062-1067 (1980)
C86	"Transition Therapeutics Confirms Effectiveness of Islet Neogenesis Therapy in Reducing Diabetic Symptoms", Transition Therapeutics Press Release, April 17, 2002
C87	"Transition Therapeutics Inc. Receives Approval to Initiate Phase I Clinical Trial for Islet Neogenesis Therapy", Transition Therapeutics Press Release, September 20, 2002
C88	"Transition Therapeutics' I.N.T.™ Treatment Stimulates Regeneration of Human Insulin-Producing Cells", Transition Therapeutics Press Release, September 26, 2002
C89	"Transition Therapeutics' I.N.T.™ Treatment Increases Survival", Transition Therapeutics Press Release, September 27, 2002
C90	Unger et al., "The Effects of Secretin, Pancreozymin, and Gastrin on Insulin and Glucagon Secretion in Anesthetized Dogs", <i>Journal of Clinical Investigation</i> , 46(4):630-645 (1967)
C91	Von Herrath, M., "EI-INT Transition Therapeutics/Novo Nordisk", <i>Current Opinion Investig Drugs</i> , 6(10): 1037-1042 (2005)
C92	Whitaker et al., "Polymeric Delivery of Protein-Based Drugs", <i>Bus Brief: Pharmatech</i> , 1-5 (2002)
C93	Ye et al., "DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs", <i>J. Controlled Rel</i> , 64:166-166 (2000)

* By the waiver of 37 CFR 1.98(a)(2)(ii) copies of the U.S. Patents A16-A22 and U.S. Published Applications A23-A24 are not submitted.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.